BIVI

BioVie Stock Price

7.9328
-0.0972 (-1.21%)
Upgrade to Real-Time
Afterhours (Closed)
7.9328
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
BioVie Inc BIVI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0972 -1.21% 7.9328 16:02:00
Close Price Low Price High Price Open Price Previous Close
7.9328 7.70 8.3843 7.90 8.03
Bid Price Ask Price Spread News
7.70 11.75 4.05 1 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
166 41,831 $ 7.96 $ 332,869 56,251 7.70 - 12.00
Last Trade Time Type Quantity Stock Price Currency
16:00:00 100 $ 8.00 USD

BioVie Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 110.39M 13.92M 9.44M $ - $ - -7.61 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 8.00%

more financials information »

BioVie News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BIVI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week9.669.667.708.3542,043-1.73-17.88%
1 Month9.6712.007.709.5537,628-1.74-17.96%
3 Months10.5012.007.709.6247,504-2.57-24.45%
6 Months10.5012.007.709.6247,504-2.57-24.45%
1 Year10.5012.007.709.6247,504-2.57-24.45%
3 Years10.5012.007.709.6247,504-2.57-24.45%
5 Years10.5012.007.709.6247,504-2.57-24.45%

BioVie Description

BioVie Inc is active in the healthcare domain in the United States. The company is a development stage enterprise engaged in the discovery, development, and commercialization of a therapy targeting ascites due to liver cirrhosis. Its therapy BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis. BioVie is developing BIV201 for alleviating the portal hypertension and correcting splanchnic vasodilation, thereby increasing effective blood volume and reducing the signals to the kidneys to retain excess salt and water.


Your Recent History
NASDAQ
BIVI
BioVie
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.